Consolidated results for the six months ended December 2026 show net sales of 15 million yen, operating loss of 2,404 million yen, and net loss attributable to owners of the parent of 2,286 million yen. Compared with the same period of the previous year, sales declined sharply while R&D expenses increased. Earnings guidance for the year ending December 2026 has not been disclosed. The company holds cash and cash equivalents of 9,074 million yen and plans to continue strengthening finances and cost reduction.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4593","jir_company_name":"Helios Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4593-20260812-01.pdf","jir_short_summary":"Consolidated results for the six months ended December 2026 show net sales of 15 million yen, operating loss of 2,404 million yen, and net loss attributable to owners of the parent of 2,286 million yen. Compared with the same period of the previous year, sales declined sharply while R&D expenses increased. Earnings guidance for the year ending December 2026 has not been disclosed. The company holds cash and cash equivalents of 9,074 million yen and plans to continue strengthening finances and cost reduction.","jir_summary":"### Overview of Performance\nHelios's interim period for the year ending December 2026 recorded net sales of 15 million yen at a low level, with an operating loss of 2,404 million yen and a net loss attributable to owners of the parent of 2,286 million yen. Compared with the same period of the previous year, sales declined sharply while R&D expenses increased. The dividend forecast is not disclosed at this time, and disclosure will continue through the earnings materials and an investor briefing. The financial position includes cash and cash equivalents of 9,074 million yen, and capital structure has improved due to new share issuances, though material uncertainty remains regarding the continuation as a going concern. In the future, management will pursue fundraising and cost control aligned with growth opportunities from UDC and cultured supernatant sales and ARDs-related drug development progress. \n\n### Outlook and Strategy\nForecast for the year ending December 2026 has not been disclosed. The company will focus on securing stable revenue sources ( UD C \/ iPS cell stock provision \/ cultured supernatant sales), and advance preparations for domestic regulatory approval of ARDs therapies. By combining pipeline partnership development, cost reductions, and fundraising, the company aims to strengthen its financial foundation and stabilize its business over the long term.","jir_financial_highlights":"Net Revenue: 15 (YoY \u25b374.9% decrease)\nOperating Loss: \u25b32,404 (YoY \u25b31,573 loss)\nIntermediate Profit: \u25b32,286 (YoY \u25b34,710 from the same period, but still in deficit)\nCash and Cash Equivalents: 9,074 (increase from the previous period)\nEnding Number of Treasury Shares: 300 shares (no significant change)","jir_category":"","jir_hashtags":"#Helios, #FinancialStatement, #InterimPeriod, #FinancialPosition","jir_key_figures":"Net Revenue: 15 million yen\nOperating Loss: \u25b32,404 million yen\nInterim Loss: \u25b32,266 million yen\nCash and Cash Equivalents: 9,074 million yen\nTreasury Shares: 300 shares","jir_meta_title":"\u3010Helios\u30112026 Annual End December Quarter 2 Financial Results\uff5cSales Slight, Losses Widen","jir_meta_description":"Helios's 2026 interim period (six months ended December 2026) results show net sales of 15 million yen and operating loss of 2,404 million yen. Increases in R&D expenses and continued interim losses, with cash on hand of 9,074 million yen. Future outlook not disclosed. Analyzing financial strategy and growth opportunities ahead.","jir_og_title":"Helios Interim Results: Low Revenue and Ongoing Deficit","jir_og_description":"Helios's 2026 interim results show low sales and expanding operating losses. Going forward, the company aims to monetize through ARDs development and cultured supernatant sales.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57247,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-102478","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n